Longform editorial from clinicians, technologists and healthcare strategists inside the ecosystem. We publish only when a piece is ready. The shelf below is honest about what is still in editorial.
These are the questions the editorial programme returns to. Each category is a body of work, not a tag.
Six pieces currently in editorial across the ecosystem. Each takes one operational question seriously; none is a marketing brochure.
Public discussion of precision medicine has been dominated by diagnostics. Yet the diagnostic is only the second link in a chain that runs from discovery, through interpretation and programme design, all the way to continuous evidence. A missing link anywhere breaks the whole system — which is why most precision innovations quietly fail to reach routine care.
Product thinking has transformed most industries. In healthcare it stalls, because the unit of value is not a feature — it is a longitudinal patient outcome. Healthcare Productisation™ borrows the discipline of product design but replaces the unit: from feature to governed pathway, from release to protocol, from user to patient followed over time.
Many precision-medicine products describe themselves as programmes. Very few actually are. A Medical Programme names its patient population, defines eligibility, sets a clinical pathway, assigns oversight, and closes an evidence loop. Anything missing from that list is not a programme; it is a product waiting to fail at implementation.
Clinical governance is usually described as something bolted on top of care — audits, sign-offs, incident reviews. In a Medical Programme it is the other way round. Governance is the design decision that determines what the programme is allowed to do, who is accountable for each decision, and how outcomes feed back into protocol. Everything else is packaging.
AI in healthcare is often framed as a spectrum from assistive to autonomous. That framing misses the point. The question is not how much the AI does, but which decisions it is allowed to make. Constitutional Separation defines that boundary structurally: technology surfaces, drafts and coordinates; clinicians decide, sign and remain accountable.
The science of precision medicine is, on any honest reading, ahead of the systems that deliver it. The rate-limiting step is no longer discovery. It is the operational layer: eligibility engines, longitudinal workflow, evidence infrastructure, and the governance that holds it together. The organisations that build that layer will define the category.
We publish when a piece changes how a reader thinks about an operational problem. We do not publish company news, product updates, event coverage or opinion untethered from delivery experience. The bar is: would a healthcare strategist forward this to their team?
